Impacts of the COVID-19 pandemic on healthcare access among patients receiving medication for opioid use disorder

•Patients receiving medication for opioid use disorder are vulnerable to COVID-19 impacts.•Negative impacts include increased drug use and difficulty accessing healthcare.•Subgroup analysis identified three distinct subgroups of substance use at enrolment.•Polysubstance use subgroup had greatest dif...

Full description

Saved in:

Bibliographic Details
Published in:	Drug and alcohol dependence Vol. 221; p. 108617
Main Authors:	Jacka, Brendan P., Janssen, Tim, Garner, Bryan R., Yermash, Julia, Yap, Kimberly R., Ball, Elizabeth L., Hartzler, Bryan, Becker, Sara J.
Format:	Journal Article
Language:	English
Published:	Ireland Elsevier B.V 01.04.2021 Elsevier Science Ltd
Subjects:	Access Adult Buprenorphine Buprenorphine - therapeutic use Clinical Trials as Topic Coronaviruses COVID-19 COVID-19 - epidemiology Cross-Sectional Studies Drug addiction Drug use Drugs Female Harm Reduction Health care Health Services Accessibility - statistics & numerical data Health Services Accessibility - trends Healthcare access Humans Latent Class Analysis Male Methadone Methadone - therapeutic use Multiple drugs Naloxone Naloxone - therapeutic use Narcotics New England - epidemiology Opiate Substitution Treatment - statistics & numerical data Opiate Substitution Treatment - trends Opioids Pandemics Patients Polls & surveys Polysubstance use Short Communication Subgroups Substance use Substance use disorder Substance-Related Disorders - drug therapy Syringe service programs Treatment programs Wraparound programmes New England Healthcare access Polysubstance use Syringe service programs Methadone Buprenorphine Opioids
ISSN:	0376-8716, 1879-0046, 1879-0046
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!